CN1575821A - Hemostatic devices and methods of making same - Google Patents

Hemostatic devices and methods of making same Download PDF

Info

Publication number
CN1575821A
CN1575821A CNA2004100766233A CN200410076623A CN1575821A CN 1575821 A CN1575821 A CN 1575821A CN A2004100766233 A CNA2004100766233 A CN A2004100766233A CN 200410076623 A CN200410076623 A CN 200410076623A CN 1575821 A CN1575821 A CN 1575821A
Authority
CN
China
Prior art keywords
cellulose
oxidized
compositions
water
hemostasis device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004100766233A
Other languages
Chinese (zh)
Other versions
CN100384489C (en
Inventor
D·L·罗尼
K·特罗格尔
B·拉姆布
B·瓦尔塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Medical SAS
Original Assignee
Ethicon SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon SAS filed Critical Ethicon SAS
Publication of CN1575821A publication Critical patent/CN1575821A/en
Application granted granted Critical
Publication of CN100384489C publication Critical patent/CN100384489C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0095—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Abstract

The present invention includes compositions suitable for use in a hemostatic device and hemostatic devices utilizing such compositions, as well as methods of making the compositions and the medical devices utilizing such compositions where the compositions contain biocompatible, oxidized cellulose particles having an average designated nominal particle size of about 0.035-4.35 mm and a biocompatible, water-soluble or water-swellable polysaccharide porous binder component.

Description

Hemostasis device and manufacture method thereof
Technical field
The present invention relates to be applicable to the compositions of hemostasis device, the hemostasis device of application said composition, and the method for preparing said composition and hemostasis device.
Background of invention
Control bleed the degree that minimize for losing blood in the surgical operation, to reduce post-operative complication and shorten operating time in the operating room be necessary and key.After oxidation and the cellulose that contains hydroxy-acid group is referred to herein as carboxyl-oxidized cellulose, because it has the performance of biodegradable performance and bactericidal haemostatic, therefore be used as local hemostatic wound dressing in many surgical operations for a long time, these surgical operations comprise neurosurgery, abdomen surgery, cardiovascular surgery, thoracic surgery, head and neck surgery, pelvis surgery and skin and operation on subcutaneous tissue.
The hemostatic wound dressing that uses comprises knit goods or the adhesive-bonded fabric that contains carboxyl-oxidized cellulose at present.Recently the oxidized cellulose that uses is the carboxyl-oxidized regenerated cellulose that contains reactive carboxylic acid group, and this cellulose is processed to increase the homogeneity of cellulose fibre.The commercially available hemostatic wound dressing of this class comprises Surgicel  absorbable hemostatics, Surgicel Nu-Knit  absorbable hemostatics and Surgicel  Fibrillar absorbable hemostatics, and all these dressing all can be from Johson ﹠amp; (branch of the Ethicon Inc. of New Jersey Somerville belongs to Johson ﹠amp to Johson Wound ManagementWorldwide; JohsonCompany) obtain.The example of the absorbable hemostatics that contains carboxyl-oxidized cellulose that other is commercially available comprises Becton Dickinson and Company (New Jersey, Morris Plains) the Curacel  oxidized regenerated cellulose powder of the Curaspon Healthcare production of Oxycel  absorbable cellulose surgical dressing of Sheng Chaning and Holland.
Because the acid pH of carboxyl-oxidized cellulose uses the hemostasis device of carboxyl-oxidized cellulose can make the rapid degeneration of the latter with comprising thrombin or fibrinogenic acid-sensitive sense hemostasis albumen when contacting.Therefore, with the carrier existing problems of carboxyl-oxidized cellulose as the biological product and the medicinal reagent of acid-sensitive sense material and other acid-sensitive sense, described acid-sensitive sense material is thrombin and Fibrinogen for example.
Except the consistency problem of carboxyl-oxidized cellulose commonly used and " acid-sensitive sense " material such as albumen, medicine etc., although the body fluid absorbability and the anastalsis of at present commercially available carboxyl-oxidized cellulose hemostat are enough in light to moderate hemorrhage application, carboxyl-oxidized cellulose can provide and keep hemostasis effectively and still belongs to the unknown in the severe haemorrhage of high relatively speed massive blood loss.Require promptly highly to stop blooding under the severe haemorrhage situation, that described situation comprises that arterypuncture, hepatectomy, the blunt wound of liver, the blunt wound of spleen, aortic aneurysm cause is hemorrhage, to patient's use that excessive anticoagulant causes hemorrhage or patient hemorrhage of coagulopathy such as hemophilia etc. arranged.
The invention provides hemostasis and antimicrobial properties be parity with or superiority over traditional hemostasis device or can with the device of " acid-sensitive sense " substances compatible, and the method for preparing this class device.
Summary of the invention
The present invention relates to be suitable for the compositions of hemostasis device and use the hemostasis device of said composition, described compositions comprises biocompatible oxidized fibre crude granule and biocompatible, the water solublity or the water-swellable polysaccharide porous adhesive ingredients of the average appointment nominal particle size with about 0.035-4.35mm.The invention still further relates to the preparation method of the medical treatment device of said composition and application said composition.
We have found some compositions, and it has utilized biocompatible oxidized fibre crude granule and biocompatible porous polysaccharide adhesive ingredients, and has the performance that is suitable in the hemostasis device.Described herein " granule " be meant and comprise and various forms ofly can combine the solid particulate materials that formation has the compositions of a fixed structure with the polymer adhesive composition, especially comprises as fiber and have regular and irregular shape form of powder.Compositions comprises porous polymer adhesive composition, so the oxidized fibre crude granule can be by the combination of binding agent composition so that compositions has physics and the chemical property that is suitable in the hemostasis device.The physical arrangement of compositions can be the form of foam or condensation product, hereinafter it has been carried out more detailed description respectively.
Use the hemostasis device of the present invention of said composition, when being used to need the hemostatic wound, can provide and keep effective hemostasis.Described herein effective hemostasis, be meant the hemostasis field the technical staff understood effectively can control and/or alleviate blood capillary, vein or arteriolar hemorrhage in the time.Effectively the further index of hemostasis can be provided by governability standard and similar standard.
In certain embodiments, hemostasis device of the present invention can provide and keep hemostasis effectively under the situation of severe haemorrhage.Described herein severe haemorrhage is meant the situation that comprises that a large amount of relatively blood is lost blood with high relatively speed.The example of severe haemorrhage includes but not limited to because that arterypuncture, hepatectomy, the blunt wound of liver, the blunt wound of spleen, aortic aneurysm cause is hemorrhage, to patient's use that excessive anticoagulant causes hemorrhage or the hemorrhage of coagulopathy such as hemophiliac arranged.Compare with the standard of operation back nursing in present for example diagnostic or the intervention blood vessel, this device can allow the patient walk about quickly.
The polymer that is used for preparing the present composition and device porous adhesive ingredients is biocompatible, water solublity or water swellable polymer.In order compositions to be had be suitable for the chemical property in the hemostasis device, water solublity or watery distension polymer and tissue be absorbing blood or other body fluid and form viscogel and adhere to tissue rapidly when contacting.The absorption liquid polymers of drying or enrichment stage interacts by hydration and body fluid.In case be applied to the bleeding part, polymer just with blood in moisture interact through hydro-combination process.Hydration not only provides the adhesion that helps hemostasis device to adhere to the bleeding part to interact, and stops blood to flow out as the sealer at hemorrhage place, thereby the hemostatic function that helps the oxidized fibre cellulose fiber to be provided.
Preferred polymers as adhesive ingredients comprises polysaccharide.This class polysaccharide includes but not limited to cellulose, alkylcellulose is methylcellulose for example, alkyl hydroxy alkyl cellulose, hydroxy alkyl cellulose, cellulose sulfuric acid ester, carboxymethyl cellulose salt, carboxymethyl cellulose, carboxyethyl cellulose, chitin (chitin), carboxymethyl chitosan, hyaluronic acid, hyaluronate, alginate, alginic acid, propylene glycol alginate, glycogen, glucosan, dextran sulfate, curdlan (curdlan), pectin, amylopectin (pullulan), xanthan gum, chrondroitin, chondroitin sulfate, Sensor Chip CM 5, the carboxymethyl chitosan, chitosan, heparin, heparin sulfate, heparan, Heparan sulfate, dermatan sulfate (dermatan sulfate), keratan sulfate (keratan sulfate), carrageenin, chitosan, starch, amylose, amylopectin (amylopectin), poly--the N-aminoglucose, polymannuronic acid (polymannuronic acid), poly-glucuronic acid, the derivant of polyguluronic acid and above-mentioned arbitrary chemical compound.
Preferably, use oxidized cellulose preparation of granules compositions of the present invention and hemostasis device.Oxidized cellulose can be unbodied, crystalline or both mixture.Oxidized cellulose can be carboxyl-oxidized cellulose or aldehyde radical-oxidized cellulose, and the two all defines in this article and describes.Oxidized cellulose can be an oxidized regenerated cellulose, compares it with not regenerated cellulose and has the more homogeneity of height.Regenerated cellulose and preparation oxidized regenerated cellulose method are described in detail in United States Patent (USP) 3,364,200 (disclosing freon formulations prepared from solutions carboxyl-oxidized cellulose) and United States Patent (USP)s 5 with oxidising agent such as dinitrogen tetroxide, 180, describe in 398 (the disclosing the perfluoro-hydrocarbon formulations prepared from solutions carboxyl-oxidized cellulose with oxidising agent such as nitrogen dioxide), two pieces of full patent texts are incorporated herein by reference.After any method oxidation, thoroughly wash carboxyl-oxidized cellulose with solvent such as carbon tetrachloride, then with 50% isopropyl alcohol (IPA) washing, wash with 99% IPA at last.The instruction of so relevant oxidized regenerated cellulose and preparation method thereof belongs to hemostasis device technical field personnel's common practise.
The oxidized fibre crude granule can be obtained by oxidized fibre cellulose fabric weaving or nonwoven.U.S. Patent number 4,626 has been described exemplary fabric in 253, and its content is incorporated herein by reference with it in full at this.The oxidized fibre crude granule can make from the fabric that is used for conventional hemostatic wound binder, this class hemostatic wound binder comprises Surgicel  absorbable hemostatics, Surgicel Nu-Knit  absorbable hemostatics, Surgicel  Fibrillar absorbable hemostatics, and all these dressing all can be from Johson ﹠amp; (branch of the Ethicon Inc. of New Jersey Somerville belongs to Johson ﹠amp to Johson Wound ManagementWorldwide; JohsonCompany) obtain, also comprise the Oxycel  absorbable cellulose surgical bandage that Becton Dickinson and Company (New Jersey, Morris Plans) produces.The Curacel  oxidized regenerated cellulose powder that the CurasponHealthcare of oxidized cellulose powder such as Holland produces also can be used in compositions of the present invention and the hemostasis device.
Embodiment of the present invention comprise the particulate use of oxidized cellulose, the oxidized fibre crude granule is obtained by absorbable hemostatic textile, this fabric is the woven WARP-KNITTING of warp thread by bright artificial silk structure, subsequently it is oxidized to the group that comprises carboxyl or aldehyde radical, wherein the amount of carboxyl or aldehyde radical can provide biodegradable performance and antibacterial activity for fabric effectively.The thickness in monolayer that being characterized as of this fabric has at least about 0.5mm, at least about 0.03g/cm 2Density, less than about 150cm 3/ sec/cm 2The porosity and at least about 3 times of dry fabric weight and every at least cm 2The liquid absorption capacity of the about 0.1g water of fabric.
Producing the particulate WARP-KNITTING of oxidized cellulose can be by the bright artificial silk structure of the total danier of about 40-80.Though absorb every one ultimate fibre of number of times preferably less than 5 daniers for avoiding prolonging, every yarn can contain the one ultimate fibre of 10-25.By spacing or better preferably at 32 woven high bulk and the Densities of obtaining down that space, the quality of fabric is about 10 or 12 (per inch 40-48 rows) 28.At least 6 pins at interval, preferably the long guide post shog at 8-12 pin interval can further increase the thickness and the density of fabric.
When oxidized cellulose is a carboxyl-oxidized cellulose, nurse one's health oxidized cellulose before use.Nurse one's health at least 6 months by oxidized cellulose is stored under the environmental condition room temperature, or quicken conditioning.Perhaps, oxidized cellulose can be about 1 hour to 48 months of exposure in the environment of about 5%-about 90% at about 4 ℃-Yue 90 ℃, relative humidity; About 4 ℃-Yue 60 ℃, relative humidity are about 72 hours to 48 months of exposure in the environment of about 30%-about 90%; About 18 ℃-Yue 50 ℃, relative humidity are about 72 hours to 366 hours of exposure in the environment of about 60%-about 80%; Or about 50 ℃, relative humidity are to expose 168 hours in about 70% the environment.
The result of conditioning is the near water soluble molecules that comprises 3% (percentage by weight) less of carboxyl-oxidized fibre crude granule, preferred about 30% (percentage by weight) of about 3%-, about 20% (percentage by weight) of 8%-more preferably from about, be more preferably about 12% (percentage by weight) of about 9%-and 10% (percentage by weight) most preferably from about.Usually, water soluble molecules is the oligosaccharide of about 5 or sugar ring still less of acid containing of replacing.Found that content when water soluble molecules reaches the about 8%, preferably about 10% time of carboxyl-oxidized cellulose, the hemostasia effect of the wound dressing that is made by this class carboxyl-oxidized cellulose is improved, and comprising obtaining the hemostatic wound at first hemorrhage again situation takes place.
The water that also will comprise about 3%-about 20% (percentage by weight) before the oxidized fibre crude granule uses, about 13% (percentage by weight) of preferably about 7%-, more preferably from about about 12% (percentage by weight) of 9%-.Can obtain the moisture and the water soluble molecules of approximate content in carboxyl-oxidized cellulose by other method.The water and/or the water soluble molecules of approximate content for example, can be provided by known sterilization technology such as gamma-rays or electron beam irradiation (e-beam irradiation).In addition, can before use water soluble molecules such as oligosaccharide be added in the oxidized fibre crude granule.As long as have the disclosed benefit of the application, those skilled in the art just can be defined as other method that oxidized cellulose provides moisture and/or water soluble molecules easily.
In some embodiments of the present invention, can use hemorrhage or other biology or therapeutic chemical compound, composition or material, for example medicine and pharmaceutical agents.As discussed above, this class reagent or chemical compound can be " acid-sensitive sense ", just be meant that they can be by acid pH (for example acid pH that hemostatic wound dressing provided of Chang Gui carboxyl-oxidation) degraded or degeneration, or can be subjected to other adverse effect influence of acid pH.Can comprise the oxidized cellulose that produces by biocompatible aldehyde radical-oxidation of polysaccharides with the hemostasis device of the present invention of sensitivity to acid substances compatible.In this class device, polysaccharide preferably contains can effectively give the aldehyde radical of the amount of modification of polysaccharides biodegradability, this just mean described polysaccharide can by body be degraded into by the resorbent composition of body or can be easily composition by body.Especially, when the degraded composition is absorbed by body, do not produce lasting chronic heterogeneous body reaction, therefore can not keep this composition lasting trace or residual at the position of transplanting.
Be used for aldehyde radical-oxidation of polysaccharides of the present invention and can include but not limited to cellulose, cellulose derivative (for example alkylcellulose such as methylcellulose, hydroxy alkyl cellulose, alkyl-hydroxyalkylcelluloswith, cellulose sulfuric acid ester, carboxymethyl cellulose salt, carboxymethyl cellulose, carboxyethyl cellulose), chitin, carboxymethyl chitosan, hyaluronic acid, hyaluronic salt, alginate, alginic acid, propylene glycol alginate, glycogen, glucosan, dextran sulfate, curdlan, pectin, amylopectin, xanthan gum, chrondroitin, chondroitin sulfate, Sensor Chip CM 5, the carboxymethyl chitosan, heparin, heparin sulfate, heparan, Heparan sulfate, dermatan sulfate, keratan sulfate, carrageenin, chitosan, starch, amylose, amylopectin, poly--the N-aminoglucose, polymannuronic acid, poly-glucuronic acid, polyguluronic acid, and the derivant of above-claimed cpd, described every kind of glycocalix is oxidizing to the aldehyde radical number that comprises the antimicrobial effective dose.
In the preferred embodiment of using aldehyde radical-oxidation of polysaccharides, polysaccharide is oxidized to guarantee the biodegradability of aldehyde radical-oxidation of polysaccharides by the method for describing herein.This class biodegradability aldehyde radical-oxidation of polysaccharides is represented by following structure I:
Wherein, x and y represent mole percent, x+y=100%, and x is about 5 for about 95-, and y is about 5-about 95; And R can be CH 2OR 3, COOR 4, sulfonic group or phosphonate group; R 3And R 4Can be H, alkyl, aryl, alkoxyl or aryloxy group, and R 1And R 2Can be H, alkyl, aryl, alkoxyl, aryloxy group, sulfonyl or phosphono.
In certain embodiments of the invention, biocompatible, biodegradability hemostasis device comprises biocompatible, biodegradability aldehyde radical-oxidized regenerated cellulose.Especially, preferably aldehyde radical-oxidized regenerated cellulose comprises the repetitive of structure I I:
Wherein, x and y represent mole percent, x+y=100%, and x is about 5 for about 95-, and y is about 5-about 95; And R can be CH 2OH, R 1And R 2Be H.
In the preferred embodiment of the invention, aldehyde radical-oxidation regeneration polysaccharide for example cellulose is gone up functional group or the reactive group that does not contain beyond the aldehyde radical substantially." be substantially free of " and be meant that polysaccharide does not contain pH that its number changes aldehyde radical-oxidation of polysaccharides character effectively or make polysaccharide less than about 4.5, more preferably less than about 5, or greater than about 9, preferably about 9.5 those functional groups or reactive group.This type of group includes but not limited to be present in usually the carboxylic acid group in the wound dressing that is made by carboxyl-oxidized cellulose.Excessive carboxylic acid group can reduce the pH of dressing so that dressing is incompatible with those sensitivity to acid materials in so low pH degraded or degeneration, and the sensitivity to acid material is thrombin for example.Other basically the group of exclusion include but not limited to sulfonyl or phosphono.
Usually, the particulate average appointment nominal particle size of oxidized cellulose of the present invention is about 0.035mm (Tyler screen size 400)-Yue 4.35mm (Tyler screen size 5).More preferably, the average appointment nominal particle size of oxidized cellulose is the about 4.35mm of about 0.68mm-.Most preferably, the particulate average appointment nominal particle size of oxidized cellulose is the about 2.20mm of about 0.80-(the Tyler screen size is 10-20).About specifying nominal particle size, be meant being evenly distributed of in allowing the scope that changes certain particle diameter herein, it has definition in ASTM E11-87.
Be used for the particulate average appointment nominal particle size scope of oxidized cellulose of the present invention and be the about 4.35mm of about 0.68mm-.Use Thomas-Wiley  Laboratory Mill (medium-sized cutting blade) above-mentioned hemostatic textile or any oxidized fibre cellulose fabric to be cut can make to the fibre length of expecting and be used for oxidized fibre crude granule of the present invention with the cutting blade of power-actuated pulverizer.The comparatively ideal pulverizer of quick comminution ratio for fabric sample is to have two fixed blades and the power drive pulverizer with four electromotors of cutting edge, and wherein four side cut high speed rotating produce the shearing behavior.For example, can make the oxidized fibre crude granule by following method: oxidized fibre cellulose fabric such as Surgicel  absorbable hemostatics, Surgicel Nu-Knit  absorbable hemostatics or Surgicel  Fibrillar absorbable hemostatics or oxidized cellulose are inserted in the stainless steel foil capsule of filled with liquid nitrogen, and the paper tinsel capsule is immersed in the liquid nitrogen.Allow the paper tinsel capsule pass through the two-wheel roller with the speed of for example 6in/min then, producing average appointment nominal particle size is the oxidized cellulose of 0.035-4.35mm.
Description of drawings
Fig. 1 is the electron microscope scanning figure (X50) of the wound dressing cross section of embodiment 1c description.
Fig. 2 a is the electron microscope scanning figure (X50) in the wound dressing front of embodiment 1c description.
Fig. 2 b is the electron microscope scanning figure (X250) in the wound dressing front of embodiment 1c description.
Fig. 3 a is the electron microscope scanning figure (X50) of the wound dressing reverse side of embodiment 1c description.
Fig. 3 b is the electron microscope scanning figure (X250) of the wound dressing reverse side of embodiment 1c description.
Fig. 4 is the electron microscope scanning figure (X50) of the wound dressing cross section of embodiment 1b description.
Fig. 5 a is the electron microscope scanning figure (X50) in the wound dressing front of embodiment 1b description.
Fig. 5 b is the electron microscope scanning figure (X250) in the wound dressing front of embodiment 1b description.
Fig. 6 a is the electron microscope scanning figure (X50) of the wound dressing reverse side of embodiment 1b description.
Fig. 6 b is the electron microscope scanning figure (X250) of the wound dressing reverse side of embodiment 1b description.
Fig. 7 is the electron microscope scanning figure (X50) of the wound dressing cross section of embodiment 1a description.
Fig. 8 a is the electron microscope scanning figure (X50) in the wound dressing front of embodiment 1a description.
Fig. 8 b is the electron microscope scanning figure (X250) in the wound dressing front of embodiment 1a description.
Fig. 9 a is the electron microscope scanning figure (X50) of the wound dressing reverse side of embodiment 1a description.
Fig. 9 b is the electron microscope scanning figure (X250) of the wound dressing reverse side of embodiment 1a description.
Figure 10 a is the electron microscope scanning figure (X50) of the hemostasis device cross section of embodiment 3 descriptions.
Figure 10 b is the electron microscope scanning figure (X250) of the hemostasis device cross section of embodiment 3 descriptions.
Figure 11 a is the electron microscope scanning figure (X50) of the hemostasis device configuration of surface of embodiment 3 descriptions.
Figure 11 b is the electron microscope scanning figure (X250) of the hemostasis device configuration of surface of embodiment 3 descriptions.
Figure 12 a is the electron microscope scanning figure (X50) of the condensation product of embodiment 4 descriptions.
Figure 12 b is the electron microscope scanning figure (X250) of the condensation product of embodiment 4 descriptions.
Figure 13 is the electron microscope scanning figure (X50) of the microfibre configuration of surface of embodiment 2 descriptions.
The specific embodiment
The compositions that is used to make hemostasis device of the present invention can be by following method preparation: at first with water solublity or the water-swellable polymer polymer solution that makes soluble in water.Use Ultra-TURRAX  T18 DIXI medium-sized (midi) disperser (Disperers)/homogenizer (Homogenizers) to come homogenize oxidized fibre crude granule (for example fiber) and polymer solution to help Dispersion of Particles in whole solution.Homogenizer is used to mix different materials to obtain uniform distribution by mechanical movement.After the oxidized cellulose Dispersion of Particles is in polymer solution, allow the such state of dispersion experience: dissolved water solublity or water-swellable polymer are solidified so that provide porous adhesive ingredients for the oxidized fibre crude granule.Removing from compositions desolvates, and to be water contain the oxidized fibre crude granule of expecting particle diameter and the porous compositions of porous polymeric adhesive ingredients with generation.
Depend on the state of homogeneous dispersion experience, said composition can be various ways.For example, said composition can be porous form of foam, and the oxidized cellulose Dispersion of Particles depends on the preparation method for compositions in porous foam glue composition, thereby forms porous foam sponge, show as Fig. 1-9b with embodiment 1a-1c in describe; Or form the porous foam beads of describing with embodiment 3 that show among Figure 10 a-11b.In this case, granule can be attached in the structure of porous foam adhesive ingredients, provides the hemostatic performance for compositions thus.The porosity characteristic of polymer adhesive composition can make binding agent be exposed to more fully in the intravital water of machine simultaneously.Compositions also can be taked the porous condensation product form of granule and polymer adhesive, as show among Figure 12 a and the 12b with embodiment 4 in describe.In this case, the adhesive ingredients of porous polymeric can present more fibrous structure, twines the inverted configuration of this and sponge or bead mutually with the oxidized fibre crude granule.Also have, the porosity characteristic of condensation product partly is that this porous is exposed in the intravital water of machine polymer adhesive more fully because the filamentary structure of adhesive ingredients produces.Under two kinds of situations, the surface area of binding agent all is maximized so that the faster and hydration more widely with the intravital water of machine, thereby has just produced faster and closed performance widely, thereby helps the hemostasis of oxidized fibre crude granule.This based composition can further be made multiple hemostasis device.
A kind of preparation method that is used for preparing the porous foam sponge composite of hemostasis device of the present invention is: water solublity or water-swellable polymer are dissolved in the polymer solution that the solvent that is suitable for polymer makes homogeneous; By homogenize, allow the oxidized fibre crude granule contact, so that the oxidized cellulose Dispersion of Particles is in polymer solution with an amount of polymer solution; Then quick freezing contain particulate polymer solution and dry from refrigerating structure/remove and desolvate, for example at preferred 0-250mtorr, the more preferably pressure of 0-200mtorr, 0 ℃--continue lyophilizing in 10-14 hour under 50 ℃ the temperature.Lyophilizing is to remove to desolvate by distillation to obtain the particulate porous foam sponge of oxidized cellulose-containing, and wherein the oxidized cellulose Dispersion of Particles is in whole porous foam adhesive ingredients.
In freeze-drying process, Several Parameters and step are important for the compositions that generation has the mechanical performance that is suitable for hemostasis device.The micropore form that forms in this class freeze-drying process is the function of mass action of macroscopic property, freezing rate, cryogenic temperature and the solution of some factors such as solution.For making the surface area maximization of porous foam bead of the present invention, polymer solution/the granule of homogenize can be at first be lower than 0 ℃, preferred quick freezing when-50 ℃ (promptly by splashing in the liquid nitrogen) approximately, then at preferred the 0-250mtorr more preferably pressure, 0 ℃ of 0-200mtorr--and continue under 50 ℃ the temperature to remove in 10-14 hour and desolvate; Obtain the particulate porous foam bead of oxidized cellulose-containing, wherein the oxidized cellulose Dispersion of Particles is in whole porous foam adhesive ingredients.
A kind of preparation method that is used for preparing the porous condensation product of hemostasis device of the present invention is: water solublity or water-swellable polymer are dissolved in the solvent that is suitable for polymer make homogeneous polymer solution; By homogenize, allow the oxidized fibre crude granule contact, so that the oxidized cellulose Dispersion of Particles is in polymer solution with an amount of polymer solution; The dispersion of homogenize is splashed in the isopropyl alcohol to precipitate water solublity or water-swellable polymer and to form the particulate fibrous condensation product of oxidized cellulose-containing, wherein the oxidized cellulose Dispersion of Particles is in condensation product, quick freezing and dry from fibrous condensation product/remove and desolvate then, for example at the more preferably pressure of 0-200mtorr of preferred 0-250mtorr, 0 ℃--continue lyophilizing in 10-14 hour under 50 ℃ the temperature, obtain the particulate porous condensation product of oxidized cellulose-containing, wherein the oxidized cellulose Dispersion of Particles is in the filamentary structure of whole porous polymer adhesive ingredients.
If the particulate ratio of water solublity or water-swellable polymer and oxidized cellulose is too low, polymer just can not provide effective closure and physically stop hemorrhagely, thereby just reduces anthemorrhagic performance.If ratio is too high, hemostasis device will be too stiff or too crisp so that do not meet operation use in the requirement of wound tissue, thereby its mechanical performance is had a negative impact, and these mechanical performances are essential to the doctor in the placement of device and the processing in the operation.The preferred weight ratio of polymer and oxidized cellulose is about 1: about 15: 85 of 99-.The preferred weight ratio of polymer and oxidized cellulose is about 3: about 10: 90 of 97-.
As mentioned above, the hemostasis device of using the compositions that said method makes can be various ways.When compositions was porous foam sponge, its thickness was preferably greater than 2.0mm.More preferably, the thickness of sponge is 2.0-10mm.Most preferably, the thickness of sponge is 2.5-5.5mm, and the particulate average appointment nominal particle size of oxidized cellulose is about 0.80mm-2.2mm.The device of using said composition must keep fabulous elasticity adapting to hemorrhage position, but and keeps good tension and pressure degree to stand the processing in the application process.Hemostasis device can be cut into different size and dimensions satisfying the needs of operation, or can be rolled-up or compress to enter irregular health anatomic region and be beneficial to be used for endoscope/or reduce the operation of invasive.
In addition, can prepare the adhesive-bonded fabric hemostasis device by compression porous foam bead or fibrous condensation product, as can be applicable in the production process of non-woven mat fabric.Foam bead or fibrous condensation product can be made certain size so that form paste or the serosity that contains bead or condensation product, paste or serosity can be applied to or be injected into whereby needs the hemostatic position.This class paste or serosity be existing report in this area, as long as have benefit disclosed by the invention, those skilled in the art can prepare this class device easily.Other embodiment of the hemostasis device of the present invention's imagination comprises that bead or condensation product are compressed or prepare hemostasis powder, hemostatic plaster or the tampon that obtains with adjuvant.
As above-mentioned, in certain embodiments of the invention, hemorrhage, biological or therapeutic chemical compound such as medicine or medicinal reagent or its mixture may be relatively more responsive to the low pH of the wound dressing that contains carboxyl-oxidized cellulose of routine, but can introduce in the hemostasis device of the present invention of application aldehyde radical-oxidized cellulose, and needn't before introducing dressing, adjust pH value.And, if will be attached on the hemostasis device, then can increase the anthemorrhagic performance of aldehyde radical-oxidized cellulose hemostasis device and reduce free hemorrhage and move the danger that enters blood flow and cause thrombosis based on the hemorrhage of protein such as thrombin, fibrin, Fibrinogen.Can hemorrhage be attached on the hemostasis device by the method for physics or chemistry.For example, the aldehyde radical covalent bonds on reagent and the polysaccharide side chain is chemically bound to reagent on the hemostasis device like this.Preferably, hemorrhage is by physically being attached on the hemostasis device and fixedly being to combine through lyophilizing with polymer mixed.
Hemostasis device by the preparation of aldehyde radical-oxidized cellulose can contain hemorrhage, and hemorrhage includes but not limited to thrombin, Fibrinogen or fibrin, and its amount must can provide under the situation of severe haemorrhage effectively stops blooding fast and keep effective hemostasis.If the hemorrhage concentration in the wound dressing is low excessively, hemorrhage just can not provide the rapid formation of grumeleuse when effective Prothrombin (proagulant) is active to be contacted with blood or blood plasma with promotion.The preferred concentration range for of thrombin is about 1% (percentage by weight) of about 0.001-in this hemostasis device.In this hemostasis device thrombin more preferably concentration range be about 0.1% (percentage by weight) of about 0.01-.The Fibrinogen preferred concentration range for is about 50% (percentage by weight) of about 0.1-in this hemostasis device.In this hemostasis device Fibrinogen more preferably concentration range be about 10% (percentage by weight) of about 2.5-.The fibrin preferred concentration range for is about 50% (percentage by weight) of about 0.1-in this hemostasis device.In this hemostasis device fibrin more preferably concentration range be about 10% (percentage by weight) of about 2.5-.
In certain embodiments, aldehyde radical-oxidized cellulose can comprise the hemorrhage with aldehyde radical reactive group of covalent bonds with it.In this class embodiment, aldehyde radical-oxidized regenerated cellulose can react with the amino that is present on thrombin, Fibrinogen or fibrinous amino acid side chain or the N-terminal residue easily, the final conjugate that forms hemorrhage and aldehyde radical-oxidized regenerated cellulose, wherein aldehyde radical-oxidized regenerated cellulose is covalently bound by reversible imine linkage and hemorrhage.Aldehyde radical-oxidized regenerated cellulose/hemorrhage conjugate that imine linkage connects can be further forms irreversible secondary amine key with Reducing agent such as sodium borohydride or sodium cyanoborohydride reaction and is connected.In this class embodiment of the present invention, hemorrhage is scattered on the surface of hemostasis device at least, preferably, is scattered in the hemostasis device to small part, reversible or irreversibly with aldehyde radical-oxidized cellulose bonding.
In the preferred embodiment of the invention, hemorrhage such as thrombin, Fibrinogen or fibrin are non-acid, make up in the aqueous solution of water miscible or water-swellable polymer (constituted), as mentioned above, this base polymer includes but not limited to methylcellulose, hydroxy alkyl cellulose, water-soluble chitosan, carboxymethyl carboxyethyl cellulose salt, chitin, hyaluronic salt, alginate, propylene glycol alginate, glycogen, glucosan, carrageenin, chitosan, starch, amylose, the derivant of poly--N-aminoglucose and their aldehyde radical-oxidation.The suspension that the aqueous solution homogenize of aldehyde radical-oxidized cellulose and hemorrhage and water miscible or water-swellable polymer obtains can the rapid lyophilizing with the method for known maintenance therapeutic activity.So make up (constituted), the hemorrhage thing will be scattered in the polymeric substrate (polymeric substrate) of freeze-drying process formation basically equably.
As long as have benefit disclosed by the invention, those skilled in the art can select suitable hemorrhage, water solublity or water-swellable polymer and their solvent according to desired concrete environment of concrete hemostasis device and performance, and the consumption of polymer and hemorrhage.
Scanning electron microscope diagram has illustrated hemostasis device of the present invention best.By dressing being cut into 1-cm with razor 2Section prepare sample.Obtain the microgram of obverse and reverse and transverse section and mount black with carbon pigment.The sample metal spraying is also detected under fine vacuum, 4KV with electronic scanner microscope (SEM).
The following examples are used for the certain embodiments of the present invention of demonstrating, and can not be interpreted as is limitation of the present invention, but helps complete description of the present invention.
Embodiment 1a:
The preparation of the CORC fabric/Na-CMC porous paster (10/40) of cutting
The sodium salt (Na-CMC is available from Aqualon  7M8SF) of 1 gram CMC is dissolved in the 99 gram deionized waters.After polymer dissolves fully, get 15 gram Na-CMC solution and transfer on the crystallizing pan that diameter is 10cm.Obtain the Surgicel Nu-Knit  fabric that diameter is 9.8cm (about 1.3 grams) with Thomas-Wiley  Laboratory Mill (medium-sized cutting blade) cutting, on average being specified nominal particle size by USA normal test sieve (screen size=10, A.S.T.M.E.-11 specification) then is the fiber of 1.7mm.The fabric that cuts is placed CMC-Na solution in the crystallizing pan.The homogenizer homogenize that the suspension of cutting fabric in CMC-Na solution placed the medium-sized disperser of Ultra-TURRAX  T18 DIXI (Disperers)/homogenizer (Homogenizers) was dispersed in the solution until loose fabric less than 5 minutes.Then the lyophilizing in dish of uniform solution is spent the night.So just, very submissive paster (basic weight=40, thickness=5mm) have been formed.At room temperature with the further vacuum drying of this paster.
Embodiment 1b:
The preparation of the CORC fabric/Na-CMC porous paster (20/40) of cutting
The sodium salt (Na-CMC is available from Aqualon  7M8SF) of 1 gram CMC is dissolved in the 99 gram deionized waters.After polymer dissolves fully, get 15 gram Na-CMC solution and transfer on the crystallizing pan that diameter is 10cm.Obtain the Surgicel Nu-Knit  fabric that diameter is 9.8cm (about 1.3 grams) with Thomas-Wiley  Laboratory Mill (medium-sized cutting blade) cutting, producing average appointment nominal particle size by USA normal test sieve (screen size=20, A.S.T.M.E.-11 specification) then is the fiber of 0.85mm.The fabric that cuts is placed CMC-Na solution in the crystallizing pan.The homogenizer homogenize that the suspension of cutting fabric in CMC-Na solution placed the medium-sized disperser/homogenizer of Ultra-TURRAX  T18 DIXI was dispersed in the solution until loose fabric less than 5 minutes.Then the lyophilizing in dish of uniform solution is spent the night.So just, very submissive paster (basic weight=40, thickness=5mm) have been formed.At room temperature with the further vacuum drying of this paster.
Embodiment 1c:
The preparation of the CORC fabric/Na-CMC porous paster (40/40) of cutting
The sodium salt (Na-CMC is available from Aqualon  7M8SF) of 1 gram CMC is dissolved in the 99 gram deionized waters.After polymer dissolves fully, get 15 gram Na-CMC solution and transfer on the crystallizing pan that diameter is 10cm.Obtain the Surgicel Nu-Knit  fabric that diameter is 9.8cm (about 1.3 grams) with Thomas-Wiley  Laboratory Mill (medium-sized cutting blade) cutting, producing average appointment nominal particle size by USA normal test sieve (screen size=40, A.S.T.M.E.-11 specification) then is the fiber of 0.43mm.The fabric that cuts is placed CMC-Na solution in the crystallizing pan.The homogenizer homogenize that the suspension of cutting fabric in CMC-Na solution placed the medium-sized disperser/homogenizer of Ultra-TURRAX  T18 DIXI was dispersed in the solution until loose fabric less than 5 minutes.Then the lyophilizing in dish of uniform solution is spent the night.So just, very submissive paster (basic weight=40, thickness=5mm) have been formed.At room temperature with the further vacuum drying of this paster.
Embodiment 2:
The preparation of CORC microfibre/Na-CMC paster
At first CORC Fibrillar is immersed in the liquid nitrogen in the stainless steel foil capsule, the LN that contains of CORCFibrillar will be housed then 2The paper tinsel capsule with the speed of 6in/min by two-wheel/roller, produce CORC powder, microfibre or the fine grained of multiple length/size.Use the USA normal test sieve (A.S.T.M.E.-11 specification) of different screen sizes (20-400) to isolate the granule of desired particle size subsequently, obtaining length is the 0.035-0.86mm microfibre.CORC granule/powder/the microfibre that makes is like this placed CMC-Na solution in the crystallizing pan.The suspension of CORC granule/powder/microfibre in CMC-Na solution placed the homogenizer homogenize of the medium-sized disperser/homogenizer of Ultra-TURRAX  T18 DIXI, be evenly dispersed in CMC-Na (the Aqualon  7M8SF) solution until loose CORC granule/powder/microfibre.Then the lyophilizing in dish of uniform solution is spent the night.So just, very submissive paster (basic weight=40, thickness=5mm) have been formed.At room temperature with the further vacuum drying of this paster.
Embodiment 3:
The preparation of the little porous small ball of CORC/Na-CMC
At first CORC Fibrillar is immersed in the liquid nitrogen in the stainless steel foil capsule, the LN that contains of CORCFibrillar will be housed then 2The paper tinsel capsule with the speed of 6in/min by two-wheel/roller, produce CORC powder, microfibre or the fine grained of multiple length/size.Isolate the granule of desired particle size subsequently with sieve.CORC granule/powder/the microfibre that makes is like this placed CMC-Na Aqualon  7M8SF solution in the crystallizing pan.The suspension of CORC granule/powder/microfibre in CMC-Na solution placed the homogenizer homogenize of the medium-sized disperser/homogenizer of Ultra-TURRAX  T18 DIXI, be evenly dispersed in CMC-Na (the Aqualon  7M8SF) solution until loose CORC granule/powder/microfibre.This uniform solution in the crystallizing pan is transferred to LN through pipe 2The pond.Freezing immediately CORC/CMC-Na suspension, producing diameter is the micropore bead that the 0.2-9mm diameter does not wait, lyophilizing is spent the night.At room temperature with the further vacuum drying of porous small ball.
Embodiment 4:
The preparation of fibrous CORC/Na-CMC condensation product
At first CORC Fibrillar is immersed in the liquid nitrogen in the stainless steel foil capsule, will be filled with the LN that contains of CORCFibrillar then 2The paper tinsel capsule with the speed of 6in/min by two-wheel/roller, produce CORC powder, microfibre or the fine grained of multiple length/size.Isolate the granule of desired particle size subsequently with sieve.CORC granule/powder/the microfibre that makes is like this placed CMC-Na Aqualon  7M8SF solution in the crystallizing pan.The suspension of CORC granule/powder/microfibre in CMC-Na solution placed the homogenizer homogenize of the medium-sized disperser/homogenizer of Ultra-TURRAX  T18 DIXI, be evenly dispersed in the CMC-Na solution until loose CORC granule/powder/microfibre.This uniform solution in the crystallizing pan is transferred in the isopropyl alcohol (IPA) pond with deposit C ORC/CMC-Na complex through pipe.From sedimentary CORC/CMC-Na complex, remove the IPA of excessive (80-95%), freezing immediately then CORC/CMC-Na complex, thereby the fibrous condensation product of generation various ways, freeze overnight.At room temperature with the further vacuum drying of fibrous condensation product.
Embodiment 5:
The anthemorrhagic performance of different materials in the otch model of Lien Sus domestica
The otch model of Lien Sus domestica is used for assessing the anthemorrhagic performance of different materials.Material is cut into the rectangle of 2.5cm * 1.5cm or by the preparation of the method described in the foregoing description.Use surgical knife on the spleen of pig, to mark the long otch of the dark 1.5cm of 0.3cm.After using test products, on otch, pressed 2 minutes with finger.Then haemostatic effect is assessed.Each reuse finger is pressed 30 seconds up to hemostasis fully.Can not in 12 minutes, hemostatic be considered to invalid.Table 1 has shown the result of assessment.
Table 1
The assessment of the anthemorrhagic performance of different materials
In each time bar, realize the percent of hemostatic sample
Material 0-2 (minute) 2-3 (minute) 3-4 (minute) 4-5 (minute) ＜12 (minute) Hemostatic is kept
Surgicel Nu-Knit  can absorb the blood agent ??0％ ??0％ ??100％ Hemorrhage again after 4 minutes
The patch of embodiment 1a ??100％ Not hemorrhage again
The patch of embodiment 1b ??100％ Not hemorrhage again
The patch of embodiment 1c ??100％ Hemorrhage again
The patch of embodiment 2 ??100％ Not hemorrhage again
The little porous small ball of the CORC/Na-CMC of embodiment 3 ??80％ ??100％ Not hemorrhage again
The fibrous condensation product of embodiment 4 ??100％ Not hemorrhage again
Surgical cloth ????0％ Hemorrhage again generation immediately

Claims (28)

1. compositions comprises:
Biocompatible oxidized fibre crude granule with average appointment nominal particle size of about 0.035-4.35mm; With
Biocompatible, porous water solublity or water-swellable polysaccharide adhesive ingredients;
Wherein said compositions is suitable in the hemostasis device.
2. the compositions of claim 1, wherein oxidized cellulose is selected from carboxyl-oxidized cellulose or aldehyde radical-oxidized cellulose.
3. the compositions of claim 2, wherein said water solublity or water-swellable polysaccharide are selected from salt, carboxymethyl cellulose and the carboxyethyl cellulose of methylcellulose, hydroxy alkyl cellulose, carboxymethyl cellulose.
4. the compositions of claim 2, wherein said water solublity or water-swellable polysaccharide are sodium carboxymethyl cellulose.
5. the compositions of claim 1, wherein said water solublity or water-swellable polysaccharide and the particulate weight ratio of described oxidized cellulose are about 1: about 20: 80 of 99-.
6. the compositions of claim 4, wherein said sodium carboxymethyl cellulose and the particulate weight ratio of described oxidized cellulose are about 3: about 10: 90 of 97-.
7. the compositions of claim 6, wherein said granule comprises fiber.
8. the compositions of claim 7, it is the about 4.35mm of about 0.68-that wherein said fiber is on average specified nominal particle size.
9. the compositions of claim 1 comprises having the particulate sponge of described oxidized cellulose, and wherein said oxidized cellulose Dispersion of Particles is in described adhesive ingredients.
10. the compositions of claim 1 comprises the condensation product of described oxidized fibre crude granule and described adhesive ingredients.
11. a hemostasis device that comprises the compositions that is fit to use, described compositions comprises:
Average biocompatible oxidized fibre crude granule of specifying nominal particle size for the about 4.35mm of about 0.035-; With
Biocompatible, porous water solublity or water-swellable polysaccharide adhesive ingredients.
12. the hemostasis device of claim 11, wherein said oxidized cellulose is selected from carboxyl-oxidized regenerated cellulose or aldehyde radical-oxidized cellulose.
13. the hemostasis device of claim 12, wherein said water solublity or water-swellable polysaccharide are selected from salt, carboxymethyl cellulose and the carboxyethyl cellulose of methylcellulose, hydroxy alkyl cellulose, carboxymethyl cellulose.
14. the hemostasis device of claim 12, wherein said water solublity or water-swellable polysaccharide are sodium carboxymethyl cellulose.
15. the hemostasis device of claim 11, the weight ratio of wherein said water solublity or water-swellable polysaccharide and described oxidized cellulose is about 1: about 20: 80 of 99-.
16. the hemostasis device of claim 14, the weight ratio of wherein said sodium carboxymethyl cellulose and described oxidized cellulose are about 3: about 10: 90 of 97-.
17. the hemostasis device of claim 16, wherein said granule comprises fiber.
18. the hemostasis device of claim 17, the average appointment nominal particle size of wherein said fiber is the about 4.35mm of about 0.68-.
19. the hemostasis device of claim 11 comprises having the particulate sponge of described oxidized cellulose, wherein said oxidized cellulose Dispersion of Particles is in described adhesive ingredients.
20. the hemostasis device of claim 11 comprises the condensation product of described cellulose grain and described adhesive ingredients.
21. the hemostasis device of claim 11 comprises the described compositions that exists with powder, patch, suppository, serosity and paste form.
22. a compositions that is suitable for hemostasis device, described compositions prepares by following step:
A kind of the have water solublity that is dissolved in the suitable solvent or the polymer solution of water-swellable polysaccharide polymer are provided,
The biocompatible oxidized fibre crude granule of the average appointment nominal particle size with the about 4.35mm of about 0.035-is provided,
Described polymer solution is contacted with described oxidized fibre crude granule, and the condition of contact is can effectively described oxidized fibre crude granule be scattered in basically equably to form basically dispersion uniformly in the whole polymer solution,
Make described polymer solution with complete discrete particles under condition for validity, solidify described basically uniformly dispersion and
Remove from solidified dispersion and desolvate, formed described compositions thus, said composition comprises described granule and porous, water solublity or water-swellable polysaccharide polymer adhesive ingredients.
23. a preparation of compositions method that is applicable to hemostasis device comprises:
A kind of the have water solublity that is dissolved in the suitable solvent or the polymer solution of water-swellable polysaccharide polymer are provided,
The biocompatible oxidized fibre crude granule of the average appointment nominal particle size with the about 4.35mm of about 0.035-is provided,
Described polymer solution is contacted with described oxidized fibre crude granule, and the condition of contact is can effectively described oxidized fibre crude granule be scattered in basically equably to form basically dispersion uniformly in the whole polymer solution,
Make described polymer solution under condition for validity, solidify described uniform basically dispersion with complete discrete particles,
Remove from solidified dispersion and desolvate, formed described compositions thus, said composition comprises described granule and porous, water solublity or water-swellable polysaccharide polymer adhesive ingredients.
24. the method for claim 23, wherein said oxidized cellulose comprises carboxyl-oxidized regenerated cellulose.
25. the method for claim 23, wherein said water solublity or water-swellable polysaccharide are selected from methylcellulose, hydroxy alkyl cellulose, carboxymethyl cellulose salt, carboxymethyl cellulose and carboxyethyl cellulose.
26. the method for claim 25, wherein said polymer are sodium carboxymethyl cellulose.
27. the method for claim 26, wherein the weight ratio of sodium carboxymethyl cellulose and described fiber or bead is about 1: about 20: 80 of 99-.
28. the method for claim 26, wherein the weight ratio of sodium carboxymethyl cellulose and fiber or bead is about 3: about 10: 90 of 97-.
CNB2004100766233A 2003-06-25 2004-06-25 Hemostatic devices and methods of making same Expired - Fee Related CN100384489C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/603,320 US20040265371A1 (en) 2003-06-25 2003-06-25 Hemostatic devices and methods of making same
US10/603320 2003-06-25

Publications (2)

Publication Number Publication Date
CN1575821A true CN1575821A (en) 2005-02-09
CN100384489C CN100384489C (en) 2008-04-30

Family

ID=33435338

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100766233A Expired - Fee Related CN100384489C (en) 2003-06-25 2004-06-25 Hemostatic devices and methods of making same

Country Status (7)

Country Link
US (2) US20040265371A1 (en)
EP (1) EP1493451B1 (en)
JP (1) JP4920177B2 (en)
CN (1) CN100384489C (en)
AT (1) ATE481115T1 (en)
DE (1) DE602004029118D1 (en)
ES (1) ES2349775T3 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361986B (en) * 2007-08-09 2013-06-05 纪欣 Modified starch absorbable or biocompatible hemostasia material and preparation method thereof
CN104321085A (en) * 2012-05-25 2015-01-28 伊西康公司 Oxidized regenerated cellulose hemostatic powders and methods of making
CN104324408A (en) * 2014-09-25 2015-02-04 沈丽青 Prescription and preparation method of composite biological hemostatic and repairing medical adhesive bandage washing liquid
WO2018090913A1 (en) * 2016-11-15 2018-05-24 广州迈普再生医学科技有限公司 Degradable and absorbable hemostatic fiber material, preparation method therefor, and hemostatic fiber article thereof
CN109152664A (en) * 2016-05-24 2019-01-04 比奥瑟发展有限公司 Hemostasis unit and the arragement construction including the hemostasis unit
CN110152054A (en) * 2018-02-13 2019-08-23 广州倍绣生物技术有限公司 Hemostatic composition and preparation method thereof

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US20080039819A1 (en) * 2006-08-04 2008-02-14 Senorx, Inc. Marker formed of starch or other suitable polysaccharide
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
EP2319449B1 (en) 2000-11-20 2016-03-09 Senorx, Inc. Tissue site markers for in vivo imaging
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9358318B2 (en) * 2004-10-20 2016-06-07 Ethicon, Inc. Method of making a reinforced absorbable multilayered hemostatic wound dressing
CN102091347A (en) 2004-10-20 2011-06-15 伊西康公司 Absorbable hemostat
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
FR2889449B1 (en) * 2005-08-05 2011-06-10 Khorionyx IMPLANTABLE PREPARATIONS
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
WO2008006083A2 (en) 2006-07-07 2008-01-10 Surmodics, Inc. Beaded wound spacer device
EP2079385B1 (en) 2006-10-23 2013-11-20 C.R.Bard, Inc. Breast marker
EP2109409B1 (en) 2006-12-12 2018-09-05 C.R.Bard, Inc. Multiple imaging mode tissue marker
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
US20090062233A1 (en) * 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
US8557874B2 (en) * 2007-11-26 2013-10-15 Epic Wound Care, Inc. Hemostatic material
US8158155B2 (en) * 2007-12-20 2012-04-17 Kimberly-Clark Worldwide, Inc. Odor control cellulose-based granules
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
CA2716010C (en) 2008-04-03 2019-10-01 Zymogenetics, Inc. Hemostatic microspheres
US9271706B2 (en) 2008-08-12 2016-03-01 Covidien Lp Medical device for wound closure and method of use
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US9889230B2 (en) * 2008-10-17 2018-02-13 Covidien Lp Hemostatic implant
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
US20120089232A1 (en) 2009-03-27 2012-04-12 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
US8828050B2 (en) 2009-05-04 2014-09-09 Oregon Biomedical Engineering Institute Hemorrhage control devices and methods
US9512237B2 (en) 2009-05-28 2016-12-06 Gp Cellulose Gmbh Method for inhibiting the growth of microbes with a modified cellulose fiber
US9512563B2 (en) 2009-05-28 2016-12-06 Gp Cellulose Gmbh Surface treated modified cellulose from chemical kraft fiber and methods of making and using same
KR101866196B1 (en) 2009-05-28 2018-07-04 게페 첼루로제 게엠베하 Modified cellulose from chemical kraft fiber and methods of making and using the same
US9511167B2 (en) 2009-05-28 2016-12-06 Gp Cellulose Gmbh Modified cellulose from chemical kraft fiber and methods of making and using the same
US8470355B2 (en) * 2009-10-01 2013-06-25 Covidien Lp Mesh implant
WO2011090410A1 (en) * 2010-01-19 2011-07-28 Sca Hygiene Products Ab Absorbent article comprising an absorbent porous foam
US20120053619A1 (en) * 2010-08-31 2012-03-01 Boston Scientific Scimed, Inc. Hemostatic compositions and methods of making and using same
US9084602B2 (en) 2011-01-26 2015-07-21 Covidien Lp Buttress film with hemostatic action for surgical stapling apparatus
US9623223B2 (en) 2011-02-16 2017-04-18 Revmedx, Inc. Wound dressings comprising a plurality of liquid-expandable articles
EP2675413B1 (en) 2011-02-16 2017-02-15 Barofsky, Andrew Wound stasis dressing for large surface wounds
US9028851B2 (en) * 2011-12-21 2015-05-12 Ethicon, Inc. Hemostatic materials and devices with galvanic particulates
WO2014062839A1 (en) 2012-10-16 2014-04-24 Surmodics, Inc. Wound packing device and methods
US9951470B2 (en) 2013-03-15 2018-04-24 Gp Cellulose Gmbh Low viscosity kraft fiber having an enhanced carboxyl content and methods of making and using the same
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
US11083822B2 (en) 2014-07-18 2021-08-10 Ethicon, Inc. Combination cellulose material and method of making same
US10201457B2 (en) 2014-08-01 2019-02-12 Surmodics, Inc. Wound packing device with nanotextured surface
US10184011B2 (en) * 2014-10-31 2019-01-22 Core Scientific Creations Ltd. Hemostatic devices with improved properties and methods of making same
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
US11382731B2 (en) 2015-02-27 2022-07-12 Covidien Lp Medical devices with sealing properties
CN107847635B (en) 2015-05-06 2021-08-27 捷锐士阿希迈公司(以奥林巴斯美国外科技术名义) Carboxymethyl chitosan sponge preparation
MA42610A (en) 2015-08-14 2018-06-20 Ethicon Inc PROCESS FOR TREATING DISEASE USING GLYCOLYTIC DEPENDENT COMPOUND
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
CN115444968B (en) * 2015-11-06 2024-04-05 伊西康公司 Compacting hemostatic cellulose aggregates
CA3004521A1 (en) 2015-11-08 2017-05-11 Omrix Biopharmaceuticals Ltd. Hemostatic composition
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
CN107754005B (en) * 2016-08-15 2021-06-15 广州倍绣生物技术有限公司 Hemostatic compositions and methods of making same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
EP4218844A1 (en) * 2018-01-12 2023-08-02 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
CN110732037B (en) 2018-07-20 2023-05-26 广州倍绣生物技术有限公司 Hemostatic paste and preparation method thereof
IL262716A (en) 2018-11-01 2018-11-29 Omrix Biopharmaceuticals Ltd Oxidized cellulose compositions
IL268572A (en) 2019-08-07 2019-09-26 Omrix Biopharmaceuticals Ltd Expandable hemostat composed of oxidized cellulose
KR20210052099A (en) 2019-10-31 2021-05-10 주식회사 삼양바이오팜 Powder type hemostatic composition and method for preparing the same
JP6997890B2 (en) * 2020-02-07 2022-01-18 花王株式会社 External composition for skin
KR102405984B1 (en) 2020-02-07 2022-06-08 카오카부시키가이샤 composition for external use on the skin
CN114681659B (en) * 2020-12-31 2023-04-18 广州迈普再生医学科技股份有限公司 Composite styptic powder and preparation method and application thereof
CN114272445B (en) * 2021-12-06 2023-02-03 盐城工学院 Hemostatic anti-adhesion material for use in vitro and in vivo and preparation method thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517772A (en) * 1945-05-11 1950-08-08 Parke Davis & Co Neutralized oxidized cellulose products
US2914444A (en) * 1950-12-12 1959-11-24 David F Smith Cellulosic hemostatic composition
US2773000A (en) * 1952-06-06 1956-12-04 Johnson & Johnson Hemostatic surgical dressings
GB942305A (en) 1958-12-23 1963-11-20 Parachem Corp Improvements in or relating to antiseptic film and method and apparatus for producing the same
NL262878A (en) 1960-03-28
US3364200A (en) * 1960-03-28 1968-01-16 Johnson & Johnson Oxidized cellulose product and method for preparing the same
US3328259A (en) * 1964-01-08 1967-06-27 Parachem Corp Dressing for a wound containing a hemostatic agent and method of treating a wound
US3328529A (en) * 1964-08-31 1967-06-27 Heath Co Phase shifting circuit for fm stereo receiver
US3868955A (en) * 1973-10-05 1975-03-04 Personal Products Co Aldehyde polysaccharide dressings
US4289824A (en) * 1977-04-22 1981-09-15 Avtex Fibers Inc. High fluid-holding alloy rayon fiber mass
DE3037513C2 (en) * 1980-10-03 1983-05-05 Steffan, Wolfgang, 8425 Neustadt Collagen wound dressing
IN159332B (en) 1983-01-28 1987-05-02 Jai Mangal Sinha Thunuguntla
JPS6087225A (en) 1983-10-18 1985-05-16 Unitika Ltd Production of fibrination promoting material
US4600574A (en) * 1984-03-21 1986-07-15 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of producing a tissue adhesive
US4626253A (en) * 1984-10-05 1986-12-02 Johnson & Johnson Products, Inc. Surgical hemostat comprising oxidized cellulose
CS253042B1 (en) * 1985-09-25 1987-10-15 Maxmilian Mozisek Haemostatical material
DE3687660T2 (en) 1986-08-25 1993-05-27 Goodrich Co B F WOUND BANDAGE AND METHOD FOR THEIR PRODUCTION.
US4840626A (en) * 1986-09-29 1989-06-20 Johnson & Johnson Patient Care, Inc. Heparin-containing adhesion prevention barrier and process
US4752466A (en) * 1987-08-31 1988-06-21 Johnson & Johnson Products, Inc. Thrombin aerosol
US5185179A (en) 1988-10-11 1993-02-09 Semiconductor Energy Laboratory Co., Ltd. Plasma processing method and products thereof
CA2004740A1 (en) 1988-12-07 1990-06-07 Cary Linsky Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process
US5134229A (en) * 1990-01-12 1992-07-28 Johnson & Johnson Medical, Inc. Process for preparing a neutralized oxidized cellulose product and its method of use
CN1035803C (en) 1990-07-24 1997-09-10 中国化工进出口总公司 Soluble hemostyptic fabric
US5180398A (en) * 1990-12-20 1993-01-19 Johnson & Johnson Medical, Inc. Cellulose oxidation by a perfluorinated hydrocarbon solution of nitrogen dioxide
US6066773A (en) 1993-03-22 2000-05-23 E. R. Squibb & Sons, Inc. Thin film dressing with absorbent border
GB2280850B (en) 1993-07-28 1997-07-30 Johnson & Johnson Medical Absorbable composite materials for use in the treatment of periodontal disease
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
EP0726749B1 (en) * 1993-11-03 2004-08-11 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
AU5638096A (en) 1995-06-07 1996-12-30 Clarion Pharmaceuticals, Inc. Non-biological patch for hemostasis
JPH0951912A (en) 1995-08-11 1997-02-25 Sekisui Plastics Co Ltd Absorber
JP2791317B2 (en) * 1995-12-26 1998-08-27 株式会社三和化学研究所 Multilayer film preparation
US5925552A (en) * 1996-04-25 1999-07-20 Medtronic, Inc. Method for attachment of biomolecules to medical devices surfaces
US5821343A (en) * 1996-04-25 1998-10-13 Medtronic Inc Oxidative method for attachment of biomolecules to surfaces of medical devices
US5945319A (en) * 1996-04-25 1999-08-31 Medtronic, Inc. Periodate oxidative method for attachment of biomolecules to medical device surfaces
US6500777B1 (en) * 1996-06-28 2002-12-31 Ethicon, Inc. Bioresorbable oxidized cellulose composite material for prevention of postsurgical adhesions
IN192791B (en) 1996-06-28 2004-05-22 Johnson & Johnson Medical
GB2314840B (en) 1996-06-28 2000-09-06 Johnson & Johnson Medical Oxidized oligosaccharides and pharmaceutical compositions
GB2314842B (en) * 1996-06-28 2001-01-17 Johnson & Johnson Medical Collagen-oxidized regenerated cellulose complexes
US5866165A (en) * 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
IE980057A1 (en) 1997-01-30 2000-11-15 Alpenstock Holdings Ltd Haemostatic aerosol composition of polyanhydroglucuronic acid and its salts
US6306154B1 (en) * 1997-06-18 2001-10-23 Bhk Holding Hemostatic system for body cavities
US20030073663A1 (en) * 1997-06-25 2003-04-17 David M Wiseman Bioabsorbable medical devices from oxidized polysaccharides
WO1999001166A1 (en) 1997-07-02 1999-01-14 Coloplast A/S A method for preparing a non-fibrous porous material
JP3114016B2 (en) * 1998-05-15 2000-12-04 株式会社ホギメディカル Wound hemostatic material having cell adhesion promoting effect
US6261679B1 (en) * 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
DE19851334C2 (en) * 1998-11-06 2000-09-28 Aventis Behring Gmbh Flexible fibrin-based wound dressing and process for its manufacture
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
US6333029B1 (en) * 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6306424B1 (en) * 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
CA2384897A1 (en) 1999-09-18 2001-03-29 Path Tech Limited Separation method
EP1216319B1 (en) 1999-09-27 2004-04-07 BHK Holding Ltd. Absorptive fabric
JP3576063B2 (en) 2000-02-22 2004-10-13 株式会社ホギメディカル Soluble wound healing hemostatic cellulose fiber containing coagulation protein and method for producing the same
US6627785B1 (en) 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
JP2001340375A (en) 2000-05-31 2001-12-11 Toyobo Co Ltd Wound coating material
WO2002002155A1 (en) 2000-07-04 2002-01-10 C.T.P. Cable Technology Procurement Ag Wound dressing comprising a therapeutically active agent
JP2002052077A (en) 2000-08-07 2002-02-19 Unitika Ltd Wound cover material and method of manufacturing it
EP1318778A4 (en) 2000-09-12 2007-06-13 Univ Virginia Commonwealth Treatment for high pressure bleeding
US6599323B2 (en) * 2000-12-21 2003-07-29 Ethicon, Inc. Reinforced tissue implants and methods of manufacture and use
DE60203364T2 (en) 2001-01-25 2005-09-01 Nycomed Pharma As CARRIER WITH SOLID FIBRINOGEN AND THROMBIN
US6800753B2 (en) * 2001-09-04 2004-10-05 University Of Iowa Research Foundation Regenerated cellulose and oxidized cellulose membranes as potential biodegradable platforms for drug delivery and tissue engineering
US7252837B2 (en) * 2002-06-28 2007-08-07 Ethicon, Inc. Hemostatic wound dressing and method of making same
US7279177B2 (en) 2002-06-28 2007-10-09 Ethicon, Inc. Hemostatic wound dressings and methods of making same
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
GB2399289B (en) 2003-03-10 2006-03-08 Johnson & Johnson Medical Ltd Hydrocolloid materials for use in wound healing
RU2235539C1 (en) 2003-04-25 2004-09-10 Филатов Владимир Николаевич Method for preparing powder-like material for bleeding cease

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361986B (en) * 2007-08-09 2013-06-05 纪欣 Modified starch absorbable or biocompatible hemostasia material and preparation method thereof
CN104321085A (en) * 2012-05-25 2015-01-28 伊西康公司 Oxidized regenerated cellulose hemostatic powders and methods of making
US9539358B2 (en) 2012-05-25 2017-01-10 Ethicon, Inc. Oxidized regenerated cellulose hemostatic powders and methods of making
CN104321085B (en) * 2012-05-25 2017-06-23 伊西康公司 Oxidized regenerated cellulose haemostatic powder and preparation method
CN104324408A (en) * 2014-09-25 2015-02-04 沈丽青 Prescription and preparation method of composite biological hemostatic and repairing medical adhesive bandage washing liquid
CN104324408B (en) * 2014-09-25 2016-05-18 沈丽青 Prescription and preparation method that medical adhesive flushing liquor is repaired in compound bio hemostasis
CN109152664A (en) * 2016-05-24 2019-01-04 比奥瑟发展有限公司 Hemostasis unit and the arragement construction including the hemostasis unit
CN109152664B (en) * 2016-05-24 2022-01-11 比奥瑟发展有限公司 Hemostatic unit and arrangement comprising the same
WO2018090913A1 (en) * 2016-11-15 2018-05-24 广州迈普再生医学科技有限公司 Degradable and absorbable hemostatic fiber material, preparation method therefor, and hemostatic fiber article thereof
CN110152054A (en) * 2018-02-13 2019-08-23 广州倍绣生物技术有限公司 Hemostatic composition and preparation method thereof

Also Published As

Publication number Publication date
US20040265371A1 (en) 2004-12-30
ES2349775T3 (en) 2011-01-11
CN100384489C (en) 2008-04-30
JP4920177B2 (en) 2012-04-18
EP1493451B1 (en) 2010-09-15
DE602004029118D1 (en) 2010-10-28
ATE481115T1 (en) 2010-10-15
EP1493451A1 (en) 2005-01-05
JP2005015484A (en) 2005-01-20
US20060233869A1 (en) 2006-10-19
US8709463B2 (en) 2014-04-29

Similar Documents

Publication Publication Date Title
CN100384489C (en) Hemostatic devices and methods of making same
Cheng et al. Preparation and characterization of 2, 2, 6, 6-tetramethylpiperidine-1-oxyl (TEMPO)-oxidized cellulose nanocrystal/alginate biodegradable composite dressing for hemostasis applications
JP6235104B2 (en) Hemostatic composition
Alizadeh et al. Microstructure and characteristic properties of gelatin/chitosan scaffold prepared by a combined freeze-drying/leaching method
CN102600013B (en) Medical flocking hemostasis material, preparation thereof and application
CN100548249C (en) Hemostatic wound dressing and preparation method thereof
JP4593277B2 (en) Wound dressing composition containing chitosan and oxidized cellulose
US8912168B2 (en) Modified starch material of biocompatible hemostasis
CN1621016A (en) Hemostatic wound dressings containing proteinaceous polymers
CN1502375A (en) hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
CN102973984B (en) Preparation method and application of composite porous scaffold
CN1509768A (en) Stopping bleeding wound dressing and textile, manufacturing and use method thereof
JP2004290650A (en) Hemostatic bandage for injury and method of making thereof
Biranje et al. Polysaccharide-based hemostats: recent developments, challenges, and future perspectives
CN106975098B (en) Composite polysaccharide hemostatic composition and preparation method and application thereof
Cheng et al. Chitin/corn stalk pith sponge stimulated hemostasis with erythrocyte absorption, platelet activation, and Ca2+-binding capabilities
Wang et al. Chitosan-based composites reinforced with antibacterial flexible wood membrane for rapid hemostasis
CN106540310B (en) Absorbable rapid hemostatic material and preparation method thereof
JP2022550247A (en) A swelling hemostatic agent composed of oxidized cellulose
CN104069535A (en) Preparation method and application of bioactive composite film hemostasis dressing
CN202605114U (en) Medical flocked hemostasis material
CN114681656A (en) Antibacterial and repairable absorbable composite polysaccharide biomaterial and preparation method and application thereof
CN1348819A (en) Freezing absorbant hemostatic cotton and its prepn
KR20230124220A (en) Citric acid crosslinked carboxymethyl cellulose-poly(ethylene glycol) superabsorbent hydrogel scaffold prepared by eco-friendly one-pot aqueous process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080430

Termination date: 20210625

CF01 Termination of patent right due to non-payment of annual fee